Fig. 9From: A Journey in Science: Immersion in the search for effective cancer immunotherapiesa CAT Scans of the first patient to respond to treatment (in 2009) with adoptive transfer of autologous lymphocytes genetically engineered to express a chimeric antigen receptor targeting CD19 (left, lymphoma burden shown with arrows); right, complete cancer regression now ongoing over 10Â years later. b In clinic with the first patient 10Â years after treatmentBack to article page